Polyrizon Initiates Usability Study for NASARIX
Polyrizon announced the initiation of a key usability study program for its lead product candidate, NASARIX, an intranasal allergy blocker designed for broad consumer use. The study marks an important value-inflection milestone in Polyrizon's development roadmap and is being conducted to confirm alignment with U.S. Food and Drug Administration requirements for critical product elements, including labeling, instructions for use, and overall user interaction. Executed in accordance with FDA human factors and usability engineering guidance, the study is intended to de-risk downstream regulatory review and support a streamlined path toward clinical development. Successful completion of the usability program will potentially provide essential regulatory evidence supporting NASARIX readiness for clinical evaluation. This milestone represents an important step toward the planned initiation of Polyrizon's clinical trials, which are expected to commence in Q3 2026, positioning the company for continued advancement along its regulatory and potential commercialization strategy.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on PLRZ
About PLRZ
About the author

Polyrizon Ltd. Explores Strategic Investments in Aviation, AI, and Defense Sectors
- Strategic Investment Exploration: Polyrizon's Board has authorized the exploration of strategic investment opportunities in high-potential sectors, particularly in defense, aviation, and artificial intelligence, aiming to generate near-term revenues and enhance financial stability through selective investments.
- Commitment to Core Medical: The company remains focused on its core medical device activities, advancing the development and clinical studies of products like PL-14 (allergy blocker) and PL-16 (viral blocker), ensuring ongoing innovation and competitiveness in the medical field.
- Strong Financial Position: With a robust cash flow and a debt-free balance sheet, Polyrizon is well-positioned to efficiently utilize resources to accelerate growth and create long-term shareholder value while maintaining full focus on its primary medical pipeline.
- Technological Innovation Development: Polyrizon is developing its proprietary Capture and Contain TM hydrogel technology, which aims to provide a barrier against viruses and allergens through nasal sprays, further enhancing its market position in the biomedical field.

Polyrizon (PLRZ) Reports Positive Preclinical Results for PL-14 Allergy Blocker
- Preclinical Study Results: Polyrizon's PL-14 Allergy Blocker demonstrated significant allergen-blocking performance in a new in-vitro study, effectively reducing allergen transfer compared to hydroxypropyl methylcellulose (HPMC) at all time points, indicating its potential to form an effective intranasal hydrogel barrier that minimizes allergen exposure to nasal tissue.
- Advancement of Development Program: Following these positive results, the company plans to advance its preclinical development program and support future clinical studies aimed at establishing PL-14's regulatory pathway and real-world clinical benefits for allergy prevention, positioning it as a viable solution in the market.
- Positive Market Reaction: In response to the favorable news, Polyrizon's stock rose 5.65% to $13.47 on Nasdaq, reflecting investor confidence in the company's research progress and market potential.
- Strategic Implications: The successful development of PL-14 could not only transform the landscape of allergy treatment but also enhance Polyrizon's competitiveness in the biopharmaceutical sector, further driving the company's positioning in the allergy prevention market.






